Last reviewed · How we verify
NCT03584048
Charlotte Retention in Care Study
trial testing Alert to provider in HIV I Infection in 6,500 participants. Completed in 31 October 2019.
31 October 2019
Quick facts
| Lead sponsor | Epividian |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 6,500 |
| Start date | 1 July 2018 |
| Primary completion | 31 October 2019 |
| Estimated completion | 31 October 2019 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Alert to provider
Conditions studied
- HIV I Infection — all drugs for HIV I Infection →
Sponsor
Epividian
Who can join
18 and older, any sex, with HIV I Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of the Charlotte Retention in Care study is to assess if clinical decision support systems (CDSS) that produce standardized alerts for measures of retention in care across clinics in the city of Charlotte, North Carolina have the ability to increase retention in care measures within clinics and in surveillance reports.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03584048
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alert to provider
Trials testing the same drug.
- NCT04147832 — Epividian / AHF: Positive Pathways - HIV Retention in Care · completed
Other recruiting trials for HIV I Infection
Currently open trials in the same condition.
- NCT06799338 — Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France · recruiting
- NCT06834113 — Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal o · NA · recruiting
- NCT07202936 — Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe · recruiting
- NCT05947890 — Evaluating the Safety and Immunogenicity of MTBVAC · Phase 2 · recruiting
- NCT05110963 — Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments · NA · active not recruiting
Other Epividian trials
Trials by the same sponsor.
- NCT05710120 — Hepatitis C Screening Alerts · completed
- NCT05725109 — Hepatitis C Diagnosis to Treatment Management · completed
- NCT05495204 — External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA · completed
- NCT04863261 — Cabenuva Injection Tracking in CHORUS · NA · completed
- NCT05104359 — COVID-19 Quantitative Antibody Titers & Booster Vaccinations · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03584048 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Epividian
- Last refreshed: 4 November 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03584048.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing